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In mice the transcription factor Elf5 is necessary for correct trophoblast development. Upon knockdown
of Elf5, TS cells display neither a decrease in proliferation nor an increase in cell death but rather an
increased propensity to differentiate. Such cells rapidly lose Sox2 and 3 expression, while transiently
upregulating the giant cell differentiation determinant gene Hand1. Other genes affected within 24 h of
Elf5 knock-down, many of which have not previously been implicated in trophoblast development,
exhibited in vivo expression domains and in vitro expression responses consistent with Elf5 having a
role in counteracting trophoblast differentiation. In an ES to TS differentiation assay using Cdx2
overexpression with Elf5 loss of function cell lines, it was shown that Elf5 is necessary to prevent
terminal trophoblast differentiation. This data thus suggest that Elf5 is a gatekeeper for the TS to
differentiated trophoblast transition thereby preventing the precocious differentiation of the undiffer-
entiated extraembryonic ectoderm.
& 2014 Elsevier Inc. All rights reserved.
Introduction
The generation of the trophoblast lineage is the ﬁrst differentiation
event that a mammalian embryo undergoes. The early specialisation
underscores the importance of this uniquely mammalian lineage as
the manager of the maternal–embryonic and maternal–foetal interac-
tions. In the mouse the early trophoblast is termed the trophectoderm
(TE), and is ﬁrst seen as a spherical epithelial layer enclosing the inner
cell mass of the blastocyst embryo. The trophectoderm overlying the
inner cell mass (polar TE) maintains a proliferative undifferentiated
state, whereas the rest of the TE, the mural trophectoderm, terminally
differentiates into primary giant cells required for implantation. The
polar TE rapidly proliferates forming a conglomeration of cells that
pushes the inner cell mass into the blastocyst cavity from about
embryonic day 5 (E5). The egg cylinder so formed consists of two parts
marked by a morphologically visible constriction. The ‘bottom’ part is
the inner cell mass/epiblast-derived embryonic ectoderm, the ‘top’
part is the polar TE-derived extraembryonic ectoderm (ExE) (Gardner,
1985; Simmons and Cross, 2005). After E5.5, the egg-cylinder tro-
phectoderm most distal to the embryonic-ExE boundary begins to
differentiate into the ectoplacental cone (EPC), a tuft of trophoblast
tissue which attaches the conceptus to the maternal endometrium.
The EPC expresses markers such as Ascl2 (Mash2) from E6.5 (Guillemot
et al., 1995) and gives rise to the spongiotrophoblast cells of the
mature chorioallantoic placenta (Tanaka et al., 1997). From gastrulation
stages (E6.25 onward) the ExE itself can be divided into a proximal and
distal domain based on ExE-markers such as Cdx2 and Bmp4, which
are homogeneously expressed at pregastrulation stages (E5.5), but are
conﬁned to the proximal ExE (PrExE: the ExE abutting the embryonic
ectoderm) by E6.5 (Donnison et al., 2005; Morsut et al., 2010). By
midgestation (E7.5), the ExE, now called the chorion, is pushed distally
by the expanding exocoelic cavity and is separated from the EPC by
the ectoplacental cavity. The chorion eventually forms the syncytio-
trophoblast cells of the inner labyrinth of the placenta.
The undifferentiated nature of the polar TE and certain of its
direct descendants, namely the ExE and chorion, has been illu-
strated by the ability to isolate trophoblast stem (TS) cells from
these tissues (Tanaka et al., 1998; Uy et al., 2002). TS cells are very
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similar to E5.5 ExE and E6.5 proximal ExE in terms of gene
expression and are committed to trophoblast lineages as shown
by embryo chimera experiments (Tanaka et al., 1998). TS cells
require Fgf signalling and ﬁbroblast conditioned medium to
prevent differentiation. The conditioned medium can be replaced
by either Activin or, less effectively, by Nodal. In vivo these signals
are believed to be supplied by the adjacent embryonic ectoderm
(Fgf2 and Nodal) and endometrium (Activin). Removal of one or
both of these signals results in the successive upregulation ﬁrst of
EPC (Mash2, Tpbpa) or syncytiotrophoblast (Gcm1) markers and
then of giant cell markers (Prolactin1/Prl3d1) (Tanaka et al., 1998;
Erlebacher et al., 2004; Natale et al., 2009).
The gene regulatory network involving trophoblast stem cell
maintenance involves a number of transcription factors including
Cdx2, Eomes, Elf5, Tfap2, Ets2, Essrb, Sox2 and Foxd3 (see Pfeffer and
Pearton, 2012, for a recent review). Some of these such as Cdx2
(Niwa et al., 2005) and Tfap2 (Kuckenberg et al., 2010; Berg et al.,
2011) have an early role in preventing the alternate fate of
embryonic pluripotency during the commitment phase of tropho-
blast development whereas others such as Essrb, Sox2 and Foxd3
may be required to maintain an undifferentiated, proliferative
state independent of lineage. The latter are thus required for both
embryonic and trophoblast stem cells. Elf5, an Ets-superfamily
member characterised by a Pointed andWinged helix DNA binding
domain, is essential to ExE maintenance as shown by loss of
function mutants in which the embryonic ectoderm directly
adjoins an EPC-like layer of trophoblast (Donnison et al., 2005).
No TS cells can be isolated from Elf5 deﬁcient embryos, indicating
that Elf5 is critical for the TS maintenance network (Donnison
et al., 2005). Further evidence for a central role of Elf5 in the
trophoblast gene regulatory network derives from work using
epigenetically altered ES cells. DNA methylation or NuRD-deﬁcient
ES cells display a propensity for upregulating expression of the
normally epigenetically silenced Elf5 gene, leading to differentiation
along the trophectodermal lineage (Ng et al., 2008; Latos et al.,
2012). Indeed, overexpression of Elf5, similar to overexpression of
Cdx2, Eomes and Tfap2 can elicit TE differentiation of ES cells
(Niwa et al., 2005; Ng et al., 2008; Kuckenberg et al., 2010). This,
and transcription factor ChIP studies, have led to the suggestion of
a positive cross regulatory trophoblast network involving these
four factors as well as Ets2 (Ng et al., 2008; Kidder and Palmer,
2010). Elf5 is expressed later than Cdx2, that is, from expanded
blastocyst stages (Pearton et al., 2011), and polar trophectoderm
expression of Cdx2 is not affected in Elf5 deﬁcient peri-implan-
taton embryos (Donnison et al., 2005), thus placing Elf5 function-
ally downstream of Cdx2. There is disagreement as to whether Elf5
can itself activate Cdx2, with one report suggesting this (Ng et al.,
2008) and another not observing such an effect (Latos et al., 2012).
Here, we investigate the cellular and gene regulatory role of Elf5 in
mouse trophoblast development. Our data supports a role of Elf5
in preventing precocious differentiation of trophoblast stem cells
by enhancing stem-like genes such as Sox2 and inhibiting expres-
sion of trophoblast differentiation markers.
Methods
Cell culture
Mouse TS cells were maintained in TS medium (Tanaka et al.,
1998) containing 70% embryonic ﬁbroblast conditioned media
containing 25 ng/ml Fgf4 (Sigma) and 1 mg/ml Heparin (Sigma).
For differentiation assays, cells were either grown solely in TS
medium (No GF), or in TS medium supplemented with Fgf/Heparin
(“No Activin”), or in TS medium with supplemented 10 ng/ml
Activin A (PreproTech 120-14) (“No Fgf”).
R1 ES cells were maintained in DMEM-F12 high glucose
medium (Life Technologies) with 20% FCS (ES cell grade) supple-
mented with 1000 U/ml LIF (ORF Genetics), 2 mM Glutamax,
0.1 mM 2-mercaptoethanol, 0.1 mM Non-Essential Amino Acids
and 1 mM sodium pyruvate (Life Technologies) and grown on
mitomycin-treated mouse embryonic ﬁbroblasts feeders. For ES
differentiation experiments, ES cells were grown on plates coated
with 0.1% w/v gelatin.
Elf5 knock-down
Elf5 was knocked down by a 4–6 h transfection with 40 pmol
siRNA and 4 ml Lipofectamine 2000 (Invitrogen) per 2 cm well in
reduced serum (5% FCS) TS-medium. The most efﬁcient Elf5
siRNAs were Elf5si1, (#733) GGAAGAAGAAUGACAGGAUGACGUA
and Elf5si2, (#337) CCAACUGCAUCUCCUUCUGUCACUU (stealth
RNAi; Invitrogen), the negative control siRNA was Invitrogen’s
Medium-GC stealth RNAi.
Immunocytochemistry and cell assays
For ﬂow-cytometric analysis, a FACScan™ (Beckton Dickinson,
BD) with an Argon laser (488 nm) was used. The data was
evaluated using Cell Quest Pro software (BD).
Proliferation assay
Cells were ﬁxed for 10 min at 37 1C in 2% PFA, chilled on ice,
pelleted and permeabilised by resuspension in 90% cold methanol.
After transfer to PBS/0.5%BSA, cells were incubated for 1 h at RT with
1:200 dilution of Serine10-phospho-Histone H3 (Mitosis Marker) -
antibodies (Upstate 06-570), then 30 min with 1:1000 dilution of an
Alexaﬂuor 488 goat antirabbit IgG antibody (Invitrogen A21206).
Washed and ﬁltered (35 mm BD ﬁlter top) cells were then analysed
by ﬂow cytometry.
Apoptosis assay
The APO™-BrdU TUNEL Assay Kit (Molecular Probes, Life
Technologies, A23210), based on end labelling of DNA strand
breaks with BrdUTP using terminal deoxynucleotidyl transferase,
was used, as per manufacturer’s protocol and Alexa 488 as well as
propidium iodide (PI) signals measured by ﬂow cytometry.
DNA content assay
DNA content was determined using PI incorporation. Cells were
ﬁxed for 24 h in ice cold 70% ethanol, re-suspended in PBS, an
equal volume of 200 mM NaHPO4/100 mM Citric Acid/pH 7.8 was
added for 10 min before centrifugation and incubation in the dark
for 430 min in 50 mg/ml PI (Invitrogen) and 50 mg/ml RNase A
(Invitrogen) in PBS, followed by ﬁltration and ﬂow cytometry.
Immunocytochemistry
Actin was visualised using Phalloidin-TRITC (10 mg/ml; 30 min;
Sigma, P1951) and nuclei by Hoechst 33342 staining (20 mg/ml;
5 min; Invitrogen).
Microarrays
The GeneChips Mouse Genome 430 2.0 Array (Affymetrix)
containing 45,000 different probe sets covering most mouse
transcripts was used. Three separate mRNA samples (biological
repeats) of each treatment were pooled per GeneChip after gel
electrophoretic veriﬁcation for RNA integrity. Three GeneChips
(biological repeats) each were used for the Elf5-si1, control siRNA,
no treatment and growth factor removal samples. Two GeneChips
each were used for the No Fgf/Heparin and No Activin samples.
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Treatments were of 24 h duration. RNA was isolated using Trizol
(Invitrogen) as per manufacturer’s instructions and after ethanol
precipitation treated with 4 μl of ampliﬁcation grade DNase I
(Invitrogen) for 1 h at 37 1C in 40 μl of DNAaseI reaction buffer
(Invitrogen) containing 2 μl RNaseOut (Invitrogen) and 50 mM
DTT. Samples were phenol/chloroform extracted and ethanol
precipitated. Subsequently, Affymetrix’s ‘One-Cycle Target Assay’
protocol encompassing Poly-A RNA Control Addition, ﬁrst and
second strand cDNA synthesis, spin-column based cDNA puriﬁca-
tion, in vitro transcription and puriﬁcation of the biotin-labelled
cRNA, was followed closely using kit components. Fragmentation
yielded the expected size distribution of between 40 and 350
bases. The hybridisation cocktails were prepared according to
Affymetrix protocols using standard lab reagents and hybridised,
washed and scanned at a commercial Affymetrix facility (Auckland
University). Raw intensity data was analysed using GenStat.
Brieﬂy, robust means analysis (RMA) was applied to the data.
RMA involves three steps: background correction to remove an
error component in the intensity readings; quantile normalisation
where each slide is normalised to have the same cumulative
frequency distribution; and summation where the median value
for each probe set is calculated. The result is a log base 2 expression
value for every gene on every slide (Baird, 2006). To estimate the
differences between treatments and the relevant control a single
channel ANOVA was performed on the data.
Quantitative PCR
RNA isolation, reverse transcription, real-time PCR and quanti-
tation procedures were performed as detailed previously (Smith
et al., 2007), with modiﬁcations as outlined in (Smith et al., 2010).
Transcripts were quantiﬁed relative to the geometric mean of the
three housekeepers (Gapdh, β-actin and β-tubulin) while normal-
ising for the unique ampliﬁcation efﬁciencies of each primer pair.
Each sample was measured in triplicate, one measurement being
of a twofold dilution. Samples not showing halving of copy
number 750% when diluted twofold were deemed to lie outside
the linear range and discarded. A no template control, RT-control
and dissociation curve analysis were included in each real-time
run. Primer details are shown in Table 1.
DNA methylation
Genomic DNA from ES cells was obtained by lysis and ethanol
precipitation. Denaturation and bisulﬁte conversion was carried
out using the EZ DNA Methylation-Gold Kit (Ngiao Diagnostics,
NZ). The bisulﬁte converted DNA was ampliﬁed using the primers
detailed in Ng et al. (2008). The forward primers had a 50 addition
of AGGAAGAGAG, the reverse primers had a 30 addition of CAGT-
AATACGACTCACTATAGGGAGAAGGCT to facilitate the sequenome
analysis. Genomic DNA from untreated mouse embryonic stem
cells untreated mouse trophoblast stem cells was ampliﬁed along
with samples of ES cells treated with 5Aza at a concentration of
2 and 10 uM for 8 days as well as a no template control.
Embryo assays
Animal procedures were conducted under the approval of the
Ruakura Animal Ethics Committee (R.A.E.C. 11183). Elf5 deﬁcient
mice were previously described (Donnison et al., 2005). Washes
refer to 5 min incubations with gentle rocking.
Whole mount in situ hybridisation (WMISH) was performed as
described (Donnison et al., 2005). The Sox2 plasmid was obtained
from Dr. E Robertson. Fragments of Cyr61, Keratin7, Ly6a and Zic3
were ampliﬁed by RT-PCR from TS cell RNA (Table 2), cloned into
pGEM-T-Easy using TA-cloning (Promega) and transcribed using
SP6 or T7 RNA polymerase depending on the orientation of
insertion. Bex1, Dcaf12L1, Fndc3c1 and Mme were ampliﬁed by
RT-PCR with the addition of restriction sites (not capitalised.
Table 1
Primers used for real-time PCR analysis.
Name Forward (50–30) Reverse (50–30) Size In t
bActin CAGAAGGACTCCTATGTGGG TTGGCCTTAGGGTTCAGGG 200 1
bTubulin TGTAGAACCCAGCCCAATTC CCTGAGGCTGAGAGATGAGG 200 1
Bex1 GAAGAGCGGAGCAGGTCTGAGAA ACCCTCTGCATCAGGTCCCA 314 2
Cdx2 GGAAGCCAAGTGAAAACCAGGA TGTTGCTGCTGCTGCTGTT 239 1
Cyr61 AAAGAGACCCGGATCTGTGAA TCCATCTTCGCATCGGAA 237 1
Csrp1 GGGAGGGTTATGGTTTTTGG TGATGCCTAAGGAGGTCAGG 250 0
Dcaf12L1 TGAGCCTATCCAGCTCACTG CACGGCATCCCATTATCTCT 253 2
Elf5 TCAAGACTGTCACAGCCGAACAA GCGCGTTCTTTCCAAATTTGTA 290 2
Eomes GCAAACAACAACAACACACA GGGGCAAGGACTTAATACCA 583 3
Ets2 TGCTCAACAACAATTCTGGA AACTGGATTGGTCCGCTTCC 301 2
Fndc3c1 CCCTTGCTTGCGCTATGAA CCAGTGATAGGAGAGCCATGA 246 1
Furin TGCCAGACCACATGACTAC CAAGGACTTGGGGGATGAA 320 3
Gapdh TGCACCACCAACTGCTTAG GATGCAGGGATGATGTTC 175 1
Hand1 CCGCCGACACCAAGCTCTCCAAGATCAA AGGAGGGAAGCTTTCGGGCTGCTGA 197 1
Hmga2 AGCCGAGGTGCATTATCTTG GGTTTGGTTTGGTTTTGGTG 201 1
Hs3st3b1 GGGTTGAACACAGGTCATCAGAA TCACCGGCCATGCAGCATAC 346 0
Keratin7 AGACGGAATGGGACCTGTGAA CAGGGACATGAGATGGACAAA 244 1
Ly6a CCATTTGAGACTTCTTGCCCATC GGTCCAGGTGCTGCCTCCATTG 243 1
Mash2 GAGCAGGAGCTGCTTGACTT TCCGGAAGATGGAAGATGTC 225 1
Mme ACGCAGCAGTCGGCAAATAA GCAAAGTCCCAATGATCCTGA 349 4
Plac1 CCAAGGGCTCATCAACGAAAT TGATGGAGGGTTTACATGCTC 229 0
Prl3d1 CCTTGTAATTCTGGAGGGACTTCAGACAA TCTGAAAGACAACTCGGCACCTCAA 227
Prss46 TTGGCTGTCAGGATTGTGAA AGTCAAAGTTCCAGCTCACCA 211 1
Secretin CGATGCTACTGCTGTTGCTG CCAGGCTGTTCTCTGGGATA 201 1
Sox2 GAGCTAGACTCCGGGCGATGAA CACGAAAACGGTCTTGCCAGTA 279 1
Sox3 GGATTCCTAGGTTCTTCTGTTGCAGTTGAA AAACACACGCACACCTGGCTATAAA 221 0
Synpo2L TCACTACCACCTACACCCAGAA CCGCCGCTTCTTAAACAT 170 1
Tpbpa GATCTCCAAGGACCTCTGAA CATAAACTTACTCCACACTGCT 216 2
Zic3 CGAGTGCACACTGGCGAGAA CATGTGTTTGCGCAGGGA 264 2
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Table 2) and inserted into the corresponding sites of pBluescriptII
vectors by standard procedures.
Proliferation assay
Embryos were ﬁxed in 4% PFA for 1 h, washed in PBT (PBS, 0.1%
Tween-20), treated overnight in 0.1% H2O2 in PBS, washed in PBT and
stored at 4 1C in PBS, 0.02% thimerosal. Following storage, embryos
were washed in PBT 330min, incubated in PBT, 1% BSA (PBT-BSA)
for 1 h then incubated in PBT-BSA, 10% heat-treated lamb serum
(Block) for 1 h before 4 1C overnight incubation with 1/200 dilution of
anti-phospho-Histone H3 Ab (Upstate Biotechnologies #06-570) in
Block. The next day embryos were rinsed and extensively washed in
PBT, 31 h, incubated in PBT-BSA for 1 h then incubated in Block for
1 hour before 4 1C overnight incubationwith 1/200 dilution of embryo
powder- treated peroxidase-coupled anti-rabbit goat antibody (Sigma,
A6154). For embryo powder Ab treatment 2 mg of acetone-extracted,
dried E14 mouse embryo powder, 0.5 ml of PBT, 5 m1 heat-inactivated
serum and 10 m1 secondary antibody were combined and rocked
gently at 4 1C for 1 h. Supernatant was recovered by 10min centrifu-
gation at 4 1C and addition of 1.5 ml Block. The next day the embryos
were rinsed and extensively washed in PBT, 31 h, followed by
220min in 0.1 M Tris pH7.4. Embryos were gently agitated for 1 h in
the dark at 4 1C in fresh 0.5 mg/ml DAB (3,30diaminobenzidine
tetrahydrochloride, Aldrich) in Tris–HCl pH7.4. H2O2 was added to a
ﬁnal concentration of 0.003% and the embryos continuously observed
for 5–20min until colour developed. Reaction was stopped by placing
embryos into H2O.
Apoptosis assay
Embryos were ﬁxed in 4% PFA for 1 h, washed in PBT and serially
dehydrated in methanol/PBT before overnight storage in methanol at
20 1C. Following serial rehydration and rinsing in PBT, embryos were
partially digested in 10 μg/ml proteinase K for 3 min, washed and
ﬁxed in 4% PFA, 0.2% gluteraldehyde for 20 min. Embryos were PBT
washed, added to 0.1% sodium borohydride in PBT for 20 min, PBT
washed, rinsed through terminal transferase (TdT) buffer (Roche) and
incubated for 3 h at 37 1C in TdT buffer, 20 μMDIG-dUTP, 20 μM dTTP,
0.3 U/μl TdT (Roche). Embryos were washed in PBT, the TdT heat
inactivated at 70 1C for 20 min, washed in MABT (0.1 M maleic acid
pH7.5, 150 mM NaCl, 0.1% Tween-20), incubated 1 h in MABT, 2%
Boehringer Blocking Reagent (BBR; Roche) 1hour, MABT, 2% BBR, 20%
heat-inactivated lamb serum (Block) 1hour before overnight 4 1C
incubation in Block with 1/2000 dilution of AP-anti -DIG antibody
(Roche). Following 35min and 31 h MABT washes, embryos
were washed in NTMT buffer (100 mM each of Tris pH9.5, NaCl,
50 mMMgCl2 1% Tween-20) and the colour developed in 1.5 ml NTMT
with 0.68 μl of 100 mg/ml NBTþ0.7 μl 50 mg/ml BCIP for 15 min.
Embryos were washed in PBT and post-ﬁxed with 4% PFA for 15 min.
Elf5 overexpression in trophoblast cells
The 4-hydroxy-tamoxifen (from here on called tamoxifen or Tx)
inducible Elf5-ERT2 construct was created by fusing the T2 mutation
of the mouse oestrogen receptor ligand-binding domain to the
carboxy-terminus of Elf5 using a 3 fragments ligation of 1. A XhoI-
NotI fragment from pPyCAGIZ (Niwa et al., 2005), 2. Pwo-polymerase
(Roche) ampliﬁed Elf5 with an improved Kozak and 50 XhoI and ClaI
sites and 30 NheI and NotI sites, removing the Elf5 stop codon by
using primers ATTCCTCGAGAATCGATACCATGGTGGACTCCGTAACCCA-
TAG and TTGCGGCCGCTGCTAGCGAGTTTCTCTTCCTGCCACCCGT, and 3.,
Pwo-polymerase ampliﬁed mouse Esr-T2with 50 NheI and 30 Stop-NotI
using primers CTCGCTAGCCGAAATGAAATGGGTGCTTCAGG and
CGAGCGGCCGCTCAGATCGTGTTGGGGAAG and pCdx2ERT2 (Niwa
et al., 2005) template. The construct was sequence veriﬁed.
TS cells were stably transfected using Lipofectamine 2000
(Invitrogen) and selected for Zeomycin resistance. For induction
experiments at least three different lines per construct were
analysed and Elf5 nuclear translocation effected using 1 mg/ml
4-hydroxy-tamoxifen (Sigma).
Construction of Elf5 loss of function ES cells.
A targeting vector (14.2 kB) was constructed using the FLEx system
(Schnutgen et al., 2008) where exon 2 of Elf5 was ﬂanked by in phase
loxP and lox2272 sites followed by a reversed GFP coding sequence
lacking a promoter and reversed loxP and lox2272 sites. This arrange-
ment allows for the removal of the Elf5 exon 2, which contains the
translational start site, and its replacement with GFP driven by the Elf5
promoter after Cre-recombination. Also included was a Neo selection
marker ﬂanked by frt sites. Linearised vector was electroporated into
heterozygous Elf5þ/ mouse ES cells. After G418 selection, successful
recombinants were conﬁrmed using Southern blot analysis. Due to
random recombination with either Elf5 allele the following genotypes
were obtained; Elf5-/FLEx and Elf5þ/FLEx. The Neo selection cassette
was removed by transient transfection of the Flp recombinase and
removal conﬁrmed by PCR and restoration of G418 sensitivity. The
Elf5-/FLEx and Elf5þ/FLEx ES cells were transiently transfected with a
Cre construct which resulted in the rearrangement of the FLEx allele
leading to the removal of the Elf5 translational start site and its
replacement with the GFP coding sequence resulting in the following
genotypes: Elf5-/GFP and Elf5þ/GFP, referred to in the text as Elf5/
and þ/ respectively. To study the ES to TS cell transition these ES cell
clones, as well as their wild type progenitor R1 ES cells were stably
transfected with a Cdx2ER construct (Niwa et al., 2005) and isolated
using Zeomycin selection.
Results
Knockdown of Elf5 in TS cells enhances differentiation
in vivo, removal of Elf5 function results in the loss of the
extraembryonic ectoderm and an inability to isolate trophoblast
stem cells (Donnison et al., 2005). This was postulated to be due to
a requirement of Elf5 for trophoblast maintenance. The cellular
basis for this could be a lack of proliferation, increased apoptosis or
Table 2
Primers (RE sites small case) used for plasmid preparations for wmish probes.
Name Forward (50–30) Reverse (50–30) Size
Bex1 ATCtctagaAAGAGGAGAAGG GGActcgagTTAGAAGCTGGTAACAGGGA 534
Cyr61 GAAGAGTGGGTTTGTGATGAA AAGAATGAGCAAGGCACCAT 765
Dcaf12L1 CCTgaatTCACTAGCTCCTTAGCCTCC CCTctcgagAACTCTCAAAGCCGACTTCT 1500
Fndc3c1 GTCtctagaGTGGTGTGCCCCAAC CTTgaattcTGATTCTGTATGT 1262
Keratin7 CATGCAGGATGTGGTGGAA CAGGGACATGAGATGGAACAAA 955
Ly6a AGTTTTATCTGTGCAGCCCTTC CCTAGAGAGGATTAGAGCACC 612
Mme AGGtctagaCAGGGAAGATGAATACTTTGA AGGctcgaGAACGGTAGTACTACCGTTG 1005
Zic3 CGAGTGCACACTGGCGAGAA AACATCACCACCACCAAGCCAT 781
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premature differentiation of trophoblast cells. As Elf5/ TS cells
cannot be derived, we knocked down Elf5 in TS cells using siRNAs.
Two siRNAs (Elf5-si1 and 2) reduced Elf5 mRNA to less than 20% of
endogenous levels within 24 h of treatment, with levels approach-
ing 10% after 48 h (see for example Fig. 3C).
Under normal culture conditions the percentage of mitotic TS
cells is close to 5%, as measured by assaying histone H3 serine 10
phosphorylation, which is most abundant during metaphase of
mitosis (Fig. 1A). Treatment with control or Elf5 knock-down
siRNAs did not signiﬁcantly change the proportion of proliferating
cells (Fig. 1A). However, removal of growth factors from the
medium caused proliferation to drop ﬁve-fold to 1%. We were
also able to observe mitotic cells stained for H3ser10P in epiblast
and the remaining trophoblast tissue of Elf5 deﬁcient embryos,
indicating that proliferation is still occurring in vivo (Fig. 1C).
We next looked for an increase in apoptosis using the TUNEL
assay. TS cells displayed very low rates of apoptosis (o1%). While
exposure to siRNAs resulted in a signiﬁcant doubling in death rate
5 days after treatment (Fig. 1B), this effect was a non-speciﬁc
response to the siRNA-transfection and could already be detected
within 48 h in control-siRNA treated samples. In contrast, apop-
tosis increased to 7.5% when growth factors were removed
(Fig. 1B). Examination of Elf5/ embryos similarly did not reveal
excessive apoptosis in vivo (Fig. 1D).
Elf5 down-regulation resulted in the appearance of numerous
giant cells in the TS colonies within six days of treatment (Fig. 2A
versus C, D). Removal of all growth factors over the same time
period led to a more complete conversion to giant cells in some
colonies (Fig. 2B). We measured the differentiation into giant cells
by making use of the polyploid nature of giant cells. Cells were
stained with propidium iodide, which binds stoichiometrically to
DNA, and the ﬂuorescence measured using ﬂow cytometry. The
number of giant cells (DNA contentZ8n; n¼haploid) was 20% of
the population in Elf5 knock-down cells, which was twice as high
than in untreated or control siRNA-treated samples (Fig. 2E). In the
positive controls, growth factor removal resulted in a third of the
culture being polyploid.
We conclude that neither a decrease in proliferation nor an
increase in cell death are responsible for the loss of the extra-
embryonic ectoderm in Elf5 mutant embryos.
Instead, Elf5 knock-down TS cells display an increased propen-
sity to differentiate, which would prematurely deplete the polar
trophectoderm/ExE of its population of self-maintaining stem-like
cells, leading to the loss of this tissue in the mutant embryos.
Knockdown of Elf5 in TS cells leads to upregulation of genes involved
in trophoblast differentiation and downregulation of ExE-speciﬁc
genes
Elf5 is a transcription factor and hence its molecular function
should be apparent by determining which genes it controls. Elf5
was knocked-down in TS cells, which were harvested soon
after siRNA treatment (24 h) so as to enrich for direct targets.
Affymetrics microarray analyses revealed modest changes in
transcription levels over this short time interval, with Elf5 levels
changing maximally (3 fold depletion). Setting a cut off of 1.8 fold
change, we obtained 21 genes that were down-regulated and ten
that were upregulated after Elf5 knock-down (Supplementary
Table 1 and Fig. 3A, B). These results were veriﬁed for 18 of the
genes using Elf5 siRNA1 and 2 and two timepoints: 24 and 48 h
Fig. 1. The role of Elf5 in trophoblast proliferation and apoptosis: (A) percentages of proliferative TS cells ﬁve days after treatment as measured by ﬂow cytometry using
antibodies against histone H3 phosphorylated at serine 10. Results are averages from 5 repeats. Con, untreated control cells; No GF, Fgf and conditioned medium removed.
Noc refers to positive control cells, treated with increasing concentration of Nocodazol (15, 30 and 50 ng/ml; 16 h) to cause mitotic arrest. (B) Flow cytometry of apoptotic
cells as determined by TUNEL assay using BrdU incorporation. *Po0.05 relative to no treatment; **Po0.01. (C) Proliferative cells in E6.2 wild type and homozygous Elf5
mutant embryos stained using anti-phospho-Histone H3 Ab. (D) Apoptotic cells in E6.7 wild type and Elf5/ mutant embryos. ExE, extraembryonic ectoderm; Epc,
ectoplacental cone.
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post-treatment (Fig. 3C). For three of the genes (Hmga2, Sox3,
Zic3), downregulation using the slightly less effective Elf5-siRNA
2 was delayed by one day compared to siRNA1. Of the genes
upregulated by Elf5 knockdown, this effect was transient for three
genes (Csrp1, Ly6a, Hand1) and not veriﬁable for one (Bex1).
Of the Elf5 dependent genes only Sox2 has been shown to be
expressed in the ExE and in trophoblast stem cells, and is required
for the derivation of such cells (Avilion et al., 2003). Of the Elf5-
inhibited genes, only Hand1 is known to be a gene implicated in
trophoblast differentiation (Riley et al., 1998). Other genes known
to be required in undifferentiated trophoblast such as Cdx2, Erf,
Ets2, Eomes, Esrrb, Tead4, Fgfr2, Furin, Pcsk6/Pace4, Ehox, Bmp4 and
Foxd3 were not affected by Elf5 knockdown (Supplementary
Table 2). Nor were genes known to be associated with trophoblast
differentiation affected (Supplementary Table 2 and Fig. S1). Gene
ontology analysis using the Ingenuity suite, of the Elf5-target
genes highlighted a function of “differentiation of cells” within
the category “cellular development” with a P-value of 4109
involving the genes Adk, Col4A1, Cyr61, Hand1, HmgA2, LgalS3,
Lin28A, Ly6a, Pkdcc, Sox2, Sox3, Ssbp2, Tgm2, Vim, Zic3 as well as
Elf5. This is consistent with Elf5 being involved in trophoblast cell
differentiation.
We addressed this hypothesis in two ways. First, we compared
the effect of Elf5 knock-down to that of growth factor removal on
gene expression. Second, we examined the in vivo spatial expres-
sion of Elf5 target genes. We reasoned that if the predominant
effect of Elf5 downregulation is the change to a more differen-
tiated trophoblast gene expression state, then most of the genes
affected by loss of Elf5 activity should also be similarly affected by
growth factor removal, a treatment that results in a stronger
phenotype (Fig. 2). While both Fgf and Activin signalling is
required to inhibit the differentiation of TS cells, their effect is
not identical as Activin predisposes cells towards the syncytiotro-
phoblast fate (Tanaka et al., 1998; Erlebacher et al., 2004; Natale
et al., 2009). Compared to Elf5 knockdown, four of the Elf5 target
genes were similarly affected by either removing Fgf or Activin,
nine genes were similarly affected by Fgf but not Activin removal
and six genes by Activin but not Fgf removal (Fig. 3B, Supplemen-
tary Table 1). The greater similarity of the gene regulatory effect of
Elf5 knock-down with loss of Fgf signalling may be explained by
Fig. 2. TS cell differentiation upon Elf5 knock-down: (A–D) TS cell colonies stained for actin (red, Phalloidin) and DNA (purple, Hoechst 33342), six days after treatment as
indicated. White triangles indicate giant cells. (E) DNA content in haploid equivalents (N) after ﬂow cytometry of permealised, Propidium Iodide-stained cells 6 days after
treatment. Each treatment was repeated four times. *Po0.05, **Po0.01 relative to the untreated control (Con).
D.J. Pearton et al. / Developmental Biology 392 (2014) 344–357 349
Fig. 3. Gene expression in TS cells after Elf5 knock-down and their response to growth factor removal: (A) heatmap of genes over or underexpressed by at least 1.8 fold 24 h
after various treatments of TS cells as measured by Affymetrics microarray analysis. Cells were treated with Elf5 siRNA1 (Elf5 KD) or by culture in the presence of no growth
factors (No GF), Activin A but not Fgf4 (No FGF) and Fgf4 but no Activin A (No Act). Expression of the various treatments were compared to TS cells transfected with control
siRNA and/or untreated cells. Blue represents genes downregulated, orange upregulated upon the respective treatment. (B) Venn diagram representation of growth factor
dependence of Elf5 regulated genes listed in panel (A). Open oval depicts number of genes not affected by growth factor removal. The area of the ovals are sized
proportionally to the number of genes. (C) Gene expression in TS cells 24 and 48 h after transfection with Elf5 siRNAs 1 and 2 (solid circle and triangle, lines), a control siRNA
(blue) and after Fgf/conditioned medium removal (-GF; orange) (n¼3), as measured in triplicate by real-time PCR. Expression normalised against three housekeepers and
against t¼0 h.
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Elf5 transcription itself being downregulated upon Fgf withdrawal,
but not Activin withdrawal (Fig. 3A, Supplementary Table 1). Thus
some of the Fgf-speciﬁc effects of growth factor removal on
trophoblast gene expression may be directly mediated by the loss
of Elf5 transcription. Overall though, growth factor removal (Fgf
and/or Activin), which is known to lead to TS cell differentiation,
caused a similar rapid down- or upregulation in the majority of the
Elf5 target genes (Fig. 3B) supporting, on a molecular level, that
Elf5 prevents trophoblast differentiation.
TS cells represent undifferentiated trophoblast cells and in vivo
have been shown, via derivation experiments, to reside in the
polar trophectoderm and subsequently in the extraembryonic
ectoderm, ExE (Tanaka et al., 1998; Uy et al., 2002). Conversely
the differentiated trophoblast lineages are contained at egg
cylinder stages within the distal-most ExE (future syncytiotropho-
blasts), ectoplacental cone (EPC; future spongiotrophoblasts) and
the giant cells (Simmons and Cross, 2005; Pfeffer and Pearton,
2012). Of the examined genes downregulated in TS cells upon loss
of Elf5 (Bex1, Cyr61, Dcaf12L1, Fndc3c1, Mme, Sox2, Zic3), all seven
were speciﬁcally expressed in the TS-containing ExE (E6.5) and/or
chorionic (E7.5) compartments of the trophoblast (Figs. 4 and 5).
Conversely, Secretin and Keratin7, which were inhibited in TS cells
by Elf5, were found by whole mount in situ hybridisation to be
speciﬁcally expressed in differentiated trophoblast/EPC (Fig. 4G and H).
Ly6a, which was transiently upregulated upon Elf5 loss (Fig. 3C),
represented an exception in being expressed in the Elf5-positive ExE
(Fig. 5B) and chorion (Fig. 4B). Apart from Zic3, which was predomi-
nantly expressed in embryonic tissues (Fig. 4F), the other nine genes
were expressed only in the trophoblast at E6.5 or E7.5, suggestive of a
dedicated function in trophoblast development.
The in vivo data thus indicates that Elf5 activates genes
associated with undifferentiated trophoblast and inhibits genes
characterising differentiated trophoblast, consistent with a role in
preventing differentiation.
Expression of Elf5 targets in the absence of Elf5
The Elf5 knock-out phenotype is background dependent and
slightly variable even within the more stringent 129-strain. In the
more severe type I mutants, no mesoderm is formed whereas type
II mutants express prospective mesoderm and anterior neurecto-
derm markers, such as Brachyury and Otx2 respectively, in an
aberrant pattern (Donnison et al., 2005). As described in Pfeffer
and Pearton (2012), some ExE-markers such as Cdx2 and Bmp4,
which are homogeneously expressed in the ExE at pregastrulation
stages (E5.5), are conﬁned to the proximal ExE (PrExE: the ExE
abutting the embryonic ectoderm) by early gastrulation (E6.5).
These proximal ExE-speciﬁc markers are lost in both type I and
type II Elf5 mutants (Donnison et al., 2005). Whole mount in situ
hybridisation showed that expression of the Elf5 positive target
Sox2 was similarly restricted to the proximal part of the ExE at
E6.5, with expression also commencing in anterior neurectoderm
(Fig. 5F). Although the trophoblast domain was lost in Elf5/
mutant embryos, Sox2 expression continued in what is likely to be
prospective neurectoderm (Fig. 5G).
A second class of ExE markers are not conﬁned to the PrExE at
E6.5 but extend into the distal ExE (DiExE) and/or EPC region. This
includes Elf5 itself as well as the targets Bex1, Cyr61 and Ly6a
(Fig. 5A,B, and D). Expression of these genes was either completely
lost or seen weakly in the distal-most trophoblast (Fig. 5A, C, and
E). The remaining distal expression suggests that these genes are
not completely Elf5 dependent for their activation.
Secretin, which is upregulated in cultured TS cells by loss of
either Elf5 or growth factors, can be ﬁrst detected at E6.5-6.75 in
the EPC (Fig. 5H). Secretin is expressed at high levels in a small
Fig. 4. in vivo expression of genes misregulated upon Elf5 knock-down in TS cells.
Whole mount in situ hybridisation of potential Elf5 target genes in early to mid-
gastrulation stage embryo. Arrow in panel (F) points to chorionic expression
domain of Zic3. Red lettering indicates genes whose expression increased upon
Elf5 knock-down. Bars represent 100 mm.
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region (EPC) in E6.5 Elf5-mutants, suggestive of precocious activa-
tion in the absence of the inhibitory inﬂuence of Elf5.
Is Elf5 sufﬁcient to maintain trophoblast stem cell character?
The loss of function studies indicated the necessity of Elf5 in
preventing the differentiation of TS cells. We next turned to the
question as to whether Elf5 could function as a master gene for
maintaining the undifferentiated trophoblast stem cell gene
regulatory state. To this end we made an inducible form of Elf5
by fusing the T2 variant of the oestrogen ligand binding domain
(ERT2) to Elf5. Upon Tx-ligand addition, the fusion protein is
released from Hsp70 binding and can translocate to the nucleus.
TS cell lines expressing the fusion protein showed cytoplasmic
localisation of the exogenous Elf5 (Fig. 6A and B). Upon Tx
addition, some of the Elf5 fusion protein could be detected in
the nucleus (Fig. 6C and D).
TS cells can be efﬁciently induced to differentiate via Fgf and
conditioned medium (Activin) withdrawal. Using the inducible
Elf5-ERT2 construct we investigated whether forced Elf5 main-
tenance was sufﬁcient to halt or reverse this differentiation.
Growth factor withdrawal for 7 days, as expected, suppressed
the stem cell markers Cdx2, Eomes and Sox2 in wild type cultures
and upregulated the differentiation markers Keratin7, Secretin,
Mash2 and Tpbpa (Fig. 6E, crosses). Interestingly, two of the
positive Elf5 targets, which are downregulated after 1 and 2 days
of growth factor removal (Fig. 3C), were expressed either at TS cell
levels (Dcaf12L1) or at 3 fold higher levels (Cyr61) when measured
at 7 days of growth factor removal (Fig. 6E), indicating an only
transitory requirement for growth factors and Elf5. Forced Elf5
expression during growth factor removal resulted in very little
change in expression of the nine markers examined (Fig. 6E,
Fig. 5. Spatial expression of potential Elf5 targets in wild type and Elf5/ embryos.
Whole mount in situ hybridisation of genes as indicated, in (A), E7.0 and (B-I), E6.5
embryos. The rightmost embryo in (A) and panels (C), (E), (G) and (I) are Elf5-deﬁcient
embryos. Bars represent 100 mm; EPC, ectoplacental cone; N-Ect, prospective (anterior)
neuroectoderm; PrExE, proximal extraembryonic ectoderm.
Fig. 6. Overexpression of Tamoxifen (Tx)-inducible Elf5 in differentiating TS cells:
(A) cytoplasmic ER antibody staining of Elf5-ERT2 fusion protein overexpressed in
TS cells. (B) Hoechst nuclear stain of cells shown in (A). (C) ER Ab staining after
4 days treatment with Tx showing partial nuclearisation of Elf5-ERT2 protein.
(D) Hoechst stain of (C). (E) Gene expression after differentiation conditions (7 days
growth in the absence of growth factors). Fold change is the ratio of gene
expression in the presence to absence of Tx, multiplied by the average difference
in expression in the presence to absence of growth factors. Thus wild type
(X) depicts the effect of differentiation whereas the circles reveal the additional
effect of Elf5-ERT2 activation by Tx. A reversal of differentiation would thus be seen
as approaching the dashed line crossing the y-axis at the value of one. Results and s.
e.m. are based on triplicate PCR results of three separate stable cell lines.
D.J. Pearton et al. / Developmental Biology 392 (2014) 344–357352
circles). We conclude that Elf5, on its own, is insufﬁcient to
counteract growth factor induced TS cell differentiation.
The role of Elf5 during the ES to trophoblast transition
Mouse ES cells can be directed towards a trophoblast fate via
overexpression of a number of trophoblast stem cell transcription
factors (reviewed in Pfeffer and Pearton, 2012), notably Cdx2, Eomes
(Niwa et al., 2005) and Elf5 (Ng et al., 2008) or via the prevention of
epigenetic silencing mechanisms (Ng et al., 2008; Latos et al., 2012). In
all cases Fgf and Activin-like signalling (via conditioned medium) was
additionally required. Of note is that in spite of culture conditions
supporting maintenance of TS cells, Elf5 overexpression led to the
formation of giant cells, which are terminally differentiated tropho-
blast (Ng et al., 2008). As we have accumulated evidence here that Elf5
normally functions to prevent trophoblast differentiation, we investi-
gated the role of Elf5 in the ES to TS transition by forcing ES cell to
differentiate in the presence or absence of Elf5.
We constructed a novel loss of function allele of Elf5 (Fig. 7) in both
wild type R1 ES and Elf5þ/ R1 cells (Donnison et al., 2005). In
exploratory experiments, we treated ES cells with the DNA main-
tenance methylase-inhibitor 5-azaCytidine (5-azaC) for 6–10 days, so
as to activate Elf5 expression via Elf5 promoter demethylation (Ng
et al., 2008). In our hands, treatment of these ES cells at even close to
pharmacological doses of 5azaC (10 μM), resulted in neither an
upregulation of Elf5 nor a reduction in the high methylation level of
the Elf5 promoter (Sequenome analysis, data not shown). In conco-
mitant control experiments, sequenome analysis of TS cells expressing
Elf5 revealed minimal methylation of the Elf5 promoter as previously
reported (Ng et al., 2008). We therefore instead made use of the
Cdx2ERT2 transfection system (Niwa et al., 2005) to drive ES to
trophoblast differentiation. In this system Tamoxifen (Tx) addition
allows nuclear translocation and thus activation of the cytoplasmically
retained fusion protein. Wild type, Elf5þ/ and Elf5/ ES cells
were stably transfected with Cdx2ERT2 and allowed to differentiate
for 6 days either in TS media or TS media with Tx addition so as to
activate exogenous Cdx2. All ES lines (3–4 of each genotype) exhibited
robust levels of the introduced pCAG-Cdx2ERT2 construct (Fig. 8).
Tamoxifen addition resulted in massive down-regulation of the
pluripotency marker Oct4 with no effect seen in the absence of Tx
(Fig. 8A), indicating that little nuclear leakage of the ER fusion protein
occurs in the absence of Tx-ligand and that the construct worked as
previously reported (Niwa et al., 2005). In wild type or Elf5 hetero-
zygous ES cells, replacement of the ES medium with TS medium
effected little change (compare ﬁrst two orange with ﬁrst two red bars
in Fig. 8A–Q). However, in the absence of Elf5, ES cells in TS medium
(i.e. in the presence of Fgf and Activin signalling; third orange bar in
Fig. 8) expressed the Elf5-inhibited genes Hand1 and Keratin7. Keratin7
in particular, was turned on at high levels, comparable to those seen in
partially differentiated TS cells (Fig. 8, dark green bars). Other
trophoblast differentiation markers such as Placental lactogen 1
(Prl3d1) and Tpbpa were also detectable only on the Elf5 deﬁcient
background, albeit at low levels compared to differentiated TE cells.
Thus even very low levels of Elf5 (Fig. 8D, ﬁrst orange bar) counteract
the expression of differentiated trophoblast markers.
After 6 days of Cdx2 induction, wild type ES cells express
numerous trophoblast stem cell markers, including Elf5, Eomes,
Spc4/Pace4, Furin and Ets2 (Fig. 8, ﬁrst light green bars). As
opposed to trophoblast stem cell markers, trophoblast differentia-
tion markers are not induced, consistent with the hypothesis that
Cdx2 is one of the key upstream trophoblast lineage determining
gense and thus is able to induce and maintain the gene regulatory
network required to maintain a trophoblast stem-like state (Pfeffer
and Pearton, 2012). The apparently anomalous acute downregula-
tion of the key pluripotency and TS marker Sox2 may be ascribed
to the strict dependence of this gene in ES cells on Oct4 activity,
which was ablated by overexpressing Cdx2 (Fig. 8).
Most notably, in the absence of Elf5 (third light green bars in Fig. 8),
Cdx2 overexpression leads to the additional activation of some but not
all trophoblast differentiation markers, including Elf5-inhibited targets
(Secretin, Hand1 and Keratin7) and Plac1, which is not directly
regulated by Elf5. The dependence on Elf5 to inhibit differentiated
trophoblast formation may be sensitive to dosage as Elf5þ/ ES cells
show an intermediate response for some genes (Keratin7; Hand1;
second light green bar in Fig. 8K and Q). While the Elf5 positive target
genes Cyr61 and Dcaf12L1 are expressed at lower levels in Elf5/
Cdx2-activated ES cells, little can be inferred from this about the cells’
differentiation status as these genes are also expressed in normal ES
cells and Cyr61 shows a dynamic expression pattern upon TS
differentiation.
We conclude from this assay that, when expressed at endo-
genous levels, Elf5 acts to prevent differentiation past a tropho-
blast stem-like state.
Discussion
Our cell culture results revealed that Elf5 knockdown in TS cells
induces differentiation over the course of several days. To distin-
guish the gene expression changes associated with differentiation
Fig. 7. Elf5 loss of function ES cells: (A) strategy for novel Elf5 loss of function allele
and creation of ES cells used for ES to TE experiments. P, loxP; 2272, lox2272; pA,
polyA site; 2, Elf5 exon 2; PGK, phosphoglycerate kinase promoter; neo, neomycin.
(B) Southern blot of initial ﬂoxed construct (F) inserted into Elf5þ/ heterozygous
or wild type ES cell line showing original restriction pattern (left) and pattern after
replacement of one wild type Elf5 allele.
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from those caused speciﬁcally by loss of Elf5 we examined the TS
transcriptome within the relatively short time span of 24 h post
siRNA transfection. This strategy has yielded a set of genes that are
likely to be direct targets of Elf5. These genes fall into two
categories with genes requiring Elf5 for their maintenance being
expressed predominantly in undifferentiated trophoblast (ExE,
Chorion) and downregulated in TS cells within 24 h of Fgf and/or
Activin/Nodal withdrawal. The second group of genes exhibit the
Fig. 8. Function of Elf5 in differentiation of ES to trophectoderm: (A)–(J) Trophoblast stem cell marker genes. (K)–(Q) Trophoblast differentiation marker genes. (A)–(Q) Gene
expression levels determined by triplicate real-time RT-PCR and normalised against the geomean of three housekeepers. Each graph represents results for ES cells either
untreated (red bars) or treated for six days by transferral to TS medium (Fgf4 and Conditioned medium; orange bars) or TS medium in the presence of 0.5 mg/ml Tx (light
green bars). For each treatment are shown from left to right: Elf5-wild type ES cells (þ/þ), Elf5 heterozygous (þ/) or homozygous (/) mutant lines. All ES lines were
stably transfected with the pCAG-Cdx2ERT2 plasmid. For comparison, normalised expression is shown in TS cells (TS) as well as TS cells allowed to differentiate for two (2) or
seven (7) days by growth factor withdrawal. Error bars represent the s.e.m. of 3–4 separate cell lines.
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reciprocal pattern: inhibited by Elf5, expressed in differentiated
trophoblast tissue and activated in TS cells upon growth factor
withdrawal. Thus upon Elf5 downregulation, cells will simulta-
neously actively lose stem cell characteristics and gain differentia-
tion characteristics. How does this relate to the known gene
regulatory networks driving trophoblast development?
Elf5 and the trophoblast stem cell maintenance gene regulatory
network
Trophoblast “master” genes have been described as having the
triple characteristics of (i), being expressed in the ExE and
necessary for isolating trophoblast stem cells; (ii), being necessary
for in vivo trophoblast development; and (iii), driving ES cells into
a trophoblast fate upon overexpression (Pfeffer and Pearton, 2012).
Of such master genes, including Cdx2, Eomes, Elf5 and Tcfap2, our
results indicated that none required Elf5 for its transcription in TS
cells. Other transcription factors implicated in maintaining the
trophoblast stem cell state, such as Ets2, Esrrb, Tead4, Ehox and
Foxd3, were also unaffected by loss of Elf5 in TS cells. Indeed the
only transcription factor gene implicated in TS cell maintenance
(for which criteria three cannot be tested as it is also expressed in
ES cells), and requiring Elf5, was Sox2. The ﬁnding that knockdown
of Elf5 does not directly affect any of the other trophoblast master
genes indicates that Elf5 is unlikely to be involved in a physiolo-
gically relevant positive feedback loop. This is at odds with the Elf5
ES/TS-cell gatekeeper model in which Elf5 has been proposed to be
able to maintain Cdx2 and Eomes expression (Ng et al., 2008).
However, for the latter model it must be borne in mind that a non-
physiological setting was employed, namely ES cells in which Elf5
is not normally expressed. Elf5 is likely to lie downstream of Cdx2
based on its later onset of expression (Pearton et al., 2011), and its
(likely indirect) induction upon Cdx2 overexpression in ES cells
(Fig. 8 and (Ng et al., 2008; Nishiyama et al., 2009)). Conversely, at
least early Cdx2maintenance is independent of Elf5 in vivo as Cdx2
transcription is unperturbed in Elf5 deﬁcient peri-implantation
(E4.5) stages (Donnison et al., 2005).
The importance of Cdx2 is best illustrated by the observation
(Pfeffer and Pearton, 2012) that of all the trophoblast master
genes, only Cdx2 has the ability, when overexpressed in ES cells,
of maintaining the resulting cells in a TS state, as opposed to
allowing them to fully differentiate down the trophoblast lineage
(Niwa et al., 2005). Our results here illustrate that Elf5 is required
for this speciﬁc ability of Cdx2. However the converse is not true.
Elf5 induction in ES cells via overexpression or epigenetic manip-
ulations can induce trophoblast markers but not maintain the TS
regulatory network, resulting in terminal differentiation (Ng et al.,
2008; Latos et al., 2012). This implies that Elf5 cannot activate and/
or maintain Cdx2 expression to levels which would maintain the
TS-state.
Elf5 and its role in maintaining a stem state via Sox genes
While Elf5 may not be critical to maintaining Cdx2 and other
trophoblast maintenance genes, it is necessary for maintaining
Sox2 and 3 levels. In the construction of heterozygous LacZ knock-
in mutants of Sox2, 2.7 kbp of sequence downstream of the open
reading frame of Sox2 was deleted (Avilion et al., 2003). This
resulted in the loss of LacZ expression in the chorion at E7.5. We
thus suspected that this region, which contains numerous poten-
tial Elf5 binding sites, encompassed an ExE/chorion speciﬁc
enhancer of Sox2. However using our pTrap vector (Pfeffer et al.,
2000) to make transgenic mouse embryos with this region we
found no trophoblast expression in 12 lines, thus preventing an
in vivo demonstration of direct TE-speciﬁc regulation of Sox2
by Elf5.
Sox2 and 3 belong to the SoxB1 subfamily of Sox transcription
factors and can substitute for each other in co-expressed cells
(Avilion et al., 2003). Sox2, while excluded from polar trophecto-
derm, is expressed in the ExE (from E5.5) and chorion, whereas
Sox3 is co-expressed in the ExE from E5.5 but turned off at E8.0
chorion stages (Wood and Episkopou, 1999; Avilion et al., 2003).
Extraembryonic loss of Sox2 precluded the isolation of TS cells and
resulted in embryonic lethality by E8.5 (Avilion et al., 2003). The
persistence of the chorion until E7.5 is likely due to Sox2 redun-
dancy with the closely related Sox3. Thus the dependency of both
genes on Elf5 activity may partly explain why the Elf5 knock-out
trophoblast phenotype is more severe than that of Sox2. Interest-
ingly, Sox2 is required for stem cell maintenance in numerous
other settings, including the central nervous system (Gomez-
Lopez et al., 2011), mammary gland (Wang et al., 2013) and ICM/
ES-cells (Avilion et al., 2003). Furthermore, activation of endogen-
ous Sox2 is the deciding event during the heterogeneous transi-
tions of differentiated cells to an induced pluripotent stem state
(Buganim et al., 2012). In particular Sox2 is required to maintain a
non-differentiative state in ES and iPS cells, that is, in cells which
need to keep the trophoblast speciﬁcation pathway repressed. Yet,
Sox2 is also required in cells which need to maintain trophoblast
speciﬁc genes, namely TS cells. Thus this requirement for, and the
strong expression of, Sox2, in what are diametrically opposed cell
populations (ES and TS cells) indicates that Sox2 is not involved in
trophoblast identity or determination and thus is unlikely to
activate the trophoblast stem cell “master” genes. Instead Sox2
and 3 likely drive a “stemness” gene regulatory subcircuit that
could include the inhibition of terminal differentiation factors and
the prevention of cell cycle exit. In this regard it is intriguing that
two other transcription factors, Esrrb and Foxd3, are similarly
required for both trophoblast development and ES cell mainte-
nance (Luo et al., 1997; Tompers et al., 2005; Feng et al., 2009).
While Sox2 and 3 require Elf5 for their expression, Elf5 is
unlikely to be sufﬁcient to maintain Sox2 expression as the Elf5
in vivo expression domain in the E6.5 trophoblast extends into the
distal ExE and EPC and is thus much larger than that of Sox2 and 3.
We noted Sox2 and 3 expression required Fgf signalling. Fgf
withdrawal resulted in a dramatic and rapid loss of Sox2/3
transcription in TS cells. This Fgf-requirement would also explain
the in vivo Sox2 and 3 restriction to the proximal ExE which abuts
the embryonic ectoderm, which has been postulated to secrete
Fgf4 to the adjacent ExE (Guzman-Ayala et al., 2004).
The role of other Elf5 targets
Nineteen other genes were identiﬁed as requiring Elf5 for
maximal transcription in TS cells. Cyr61, Dcaf12L1, Bex1, Mme,
Zic3 and Fndc3c1 were all speciﬁcally expressed only in the ExE
region of the trophoblast, as expected of Elf5 positive targets. Of
these, only Cyr61, coding for a secreted matricellular protein that
functions as a ligand for integrin receptors, had been previously
shown to be expressed in the trophoblast (Mo et al., 2002). Loss of
function of Cyr61 led to embryo mortality from E10.5 due to
defects in chorioallantoic fusion and subsequent blood vessel
defects at the chorioallantoic junction (Mo et al., 2002). The
roles of the other positive Elf5 targets are either unknown
(Fndc3c, 1190003J15Rik) or heterogeneous, potentially affecting cell
integrity (Vimentin, Synpo2L), genome stability (Ssbp2), metabo-
lism (ADK, Pdk1), protein processing (Mme, PRSS46), signalling
(Hs3st3b1, Sh3bgrl, Ppap2b) or transcription (Bex1, Zic3, HMGA2,
Lin28a). Elf5 inhibited genes are similarly of heterogenous func-
tion. The novel expression domain of the Elf5-inhibited gene
Secretin in differentiated trophoblast warrants further investiga-
tion as this gene codes for a glucagon-like gastrointestinal
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hormone that functions primarily as a neuroactive peptide (Sekar
and Chow, 2013).
When comparing Elf5 positive targets with Elf5 inhibited
genes, two instances of reciprocal function are apparent. PRSS46,
which codes for a serine protease is positively regulated by Elf5,
while the serine protease inhibitor Serpinb9b is negatively regu-
lated by Elf5. Secondly, the type III intermediate ﬁlament protein
Vimentin is upregulated by Elf5 at the expense of the type II
Keratin7. Vimentin is associated with stem cells as well as cells
having undergone epithelial mesenchymal transition (EMT) to
form stem-like cells (Mani et al., 2008). During EMT, Keratin7
expression is lost concomitantly with Vimentin upregulation, a
process that is reversible by knocking down Vimentin expression
(Paccione et al., 2008). While it is unclear whether simultaneous
expression of Vimentin and Keratin7 in TS cells would be deleter-
ious, the active inhibition of Keratin7 by Elf5 ensures it’s in vivo
exclusion from the ExE, as shown here. Keratin 7 is required in
giant cells where it, together with other type II Keratins and their
type I Keratin partners (K18 and K19) are required to prevent giant
cell lysis as well as defective keratin-dependent glucose transpor-
ter localisation leading to embryonic lethality by E9.5 (Hesse et al.,
2000; Vijayaraj et al., 2009).
The upregulation of Hand1 in TS cells after Elf5 knockdown, as
well as during Fgf/Activin and Cdx2 treatment of ES cells, is likely
to be an important function of Elf5. Hand1 is expressed in all
trophectoderm by E7, but is expressed at lower levels in the ExE
(Cross et al., 1995; Yamada et al., 2006), consistent with a down-
regulation by Elf5. In vivo loss of function of Hand1 results in
embryo lethality by E7.5 because of a severe defect in trophoblast
differentiation (Riley et al., 1998). Hand1 overexpression drives TS
cells to differentiate to giant cells even in the presence of Fgf
(Hughes et al., 2004). Thus levels of this helix loop helix transcrip-
tion factor have to be kept in check to prevent precocious
differentiation as is seen in Elf5 deﬁcient embryos.
In conclusion, Elf5 acts relatively far downstream in the gene
regulatory circuitry preventing precocious differentiation of tro-
phoblast progenitors, aiding to establish undifferentiated stem-
like cells via Sox2 and 3, while simultaneously directly inhibiting
differentiation through Hand1 repression.
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